DK3050574T3 - Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom - Google Patents
Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom Download PDFInfo
- Publication number
- DK3050574T3 DK3050574T3 DK15152886.6T DK15152886T DK3050574T3 DK 3050574 T3 DK3050574 T3 DK 3050574T3 DK 15152886 T DK15152886 T DK 15152886T DK 3050574 T3 DK3050574 T3 DK 3050574T3
- Authority
- DK
- Denmark
- Prior art keywords
- plerixafor
- prevention
- treatment
- pulmonary disease
- chronic obstructive
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title 1
- 230000009798 acute exacerbation Effects 0.000 title 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 title 1
- 229960002169 plerixafor Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15152886.6A EP3050574B1 (en) | 2015-01-28 | 2015-01-28 | Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3050574T3 true DK3050574T3 (da) | 2020-01-20 |
Family
ID=52434596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15152886.6T DK3050574T3 (da) | 2015-01-28 | 2015-01-28 | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
Country Status (12)
Country | Link |
---|---|
US (1) | US10813911B2 (da) |
EP (2) | EP3613435A1 (da) |
JP (1) | JP7127988B2 (da) |
CN (1) | CN107405405B (da) |
AU (1) | AU2016212067B2 (da) |
BR (1) | BR112017016347A2 (da) |
CA (1) | CA2972319C (da) |
DK (1) | DK3050574T3 (da) |
EA (1) | EA201791689A1 (da) |
ES (1) | ES2764840T3 (da) |
IL (1) | IL253688B2 (da) |
WO (1) | WO2016120369A1 (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017127810A1 (en) * | 2016-01-22 | 2017-07-27 | Indiana University Research & Technology Corporation | Methods for repairing lung tissue |
TWI734027B (zh) * | 2017-09-18 | 2021-07-21 | 泰宗生物科技股份有限公司 | 用於治療癌症之組合物 |
EP4085910A1 (en) * | 2021-05-05 | 2022-11-09 | 4Living Biotech | Use of a compound such as plerixafor for treating a viral pulmonary disease |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
DE69434878T3 (de) | 1993-09-14 | 2014-07-17 | Imperial Innovations Ltd. | Eotaxin = eosinophil chemotaktisches cytokin |
JP3367581B2 (ja) | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするdna、そのdnaからなるベクター、そのベクターで形質転換された宿主細胞 |
US6806061B1 (en) | 1995-01-19 | 2004-10-19 | Children's Medical Center Corporation | G protein-coupled receptor gene and methods of use therefor |
US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
CA2256492C (en) | 1996-05-20 | 2006-04-04 | Teijin Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
CA2278309A1 (en) | 1997-01-21 | 1998-07-23 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
KR100447553B1 (ko) | 1997-02-26 | 2004-09-08 | 화이자 인코포레이티드 | 헤테로아릴-헥사노산 아미드 유도체, 그의 제조 방법 및 mip-1 알파의 ccr1 수용체로의 결합에 대한 선택적 저해제로서의 용도 |
US6207155B1 (en) | 1997-05-07 | 2001-03-27 | Schering Corporation | Method of eosinophil depletion with antibody to CCR 3 receptor |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AU763325B2 (en) | 1998-01-15 | 2003-07-17 | King's College London | Ribozymal nucleic acids cleaving CCR5 or CXCR4 |
EP1056778B1 (en) | 1998-02-27 | 2007-12-26 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | G protein-coupled receptor antagonists |
US6180348B1 (en) | 1998-04-20 | 2001-01-30 | Weihua Li | Method of isolating target specific oligonucleotide ligands |
CA2235420A1 (en) | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
US6429308B1 (en) | 1998-11-24 | 2002-08-06 | Hisamitsu Pharmaceutical Co., Inc. | HIV infection inhibitors |
US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
EP1163238B1 (en) | 1999-03-24 | 2006-05-31 | Anormed Inc. | Chemokine recpetor binding heterocyclic compounds |
AU2001233277B2 (en) | 2000-02-03 | 2004-06-03 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
NZ521182A (en) | 2000-03-03 | 2004-11-26 | Cambridge Antibody Tech | Human antibodies against eotaxin comprising VH adn VL domains and their use |
US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
WO2002062850A2 (en) | 2001-02-02 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
US20050124569A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
WO2003048083A2 (en) | 2001-11-30 | 2003-06-12 | Biogen Idec Ma Inc. | Antibodies against monocyte chemotactic proteins |
AR041786A1 (es) | 2002-03-15 | 2005-06-01 | Novartis Ag | Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento |
GB0212357D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
WO2004004731A1 (en) | 2002-07-02 | 2004-01-15 | F. Hoffmann-La Roche Ag | 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix |
US7964194B2 (en) | 2002-11-15 | 2011-06-21 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation |
RU2005129550A (ru) | 2003-02-27 | 2006-07-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Антагонисты рецептора ccr-3 |
US20050069955A1 (en) | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
AR046594A1 (es) | 2003-10-16 | 2005-12-14 | Applied Research Systems | Usos terapeuticos de variantes de quemoquina |
WO2005080410A1 (en) | 2004-02-20 | 2005-09-01 | Genesis Research And Development Corporation Limited | Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders |
BRPI0511599A (pt) | 2004-05-26 | 2008-01-02 | Janssen Pharmaceutica Nv | mercaptoimidazóis como antagonistas receptores de ccr2 |
CA2582225A1 (en) | 2004-09-28 | 2006-04-06 | Mingde Xia | Substituted dipiperdine ccr2 antagonists |
EP1838321A4 (en) | 2005-01-07 | 2009-03-18 | Univ Emory | CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
PE20061444A1 (es) | 2005-05-19 | 2007-01-15 | Centocor Inc | Anticuerpo anti-mcp-1, composiciones, metodos y usos |
GB0517966D0 (en) | 2005-09-02 | 2005-10-12 | Novartis Ag | Organic compounds |
HUP0500877A2 (en) | 2005-09-22 | 2007-05-29 | Sanofi Aventis | Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates |
WO2007147026A2 (en) | 2006-06-15 | 2007-12-21 | Centocor, Inc. | Ccr2 antagonists for chronic organ transplantation rejection |
JP5581055B2 (ja) | 2006-10-27 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピペリジル−プロパン−チオールccr3モジュレーター |
DK2160221T3 (da) | 2007-05-30 | 2011-09-19 | Lilly Co Eli | Cykliske peptid-CXCR4-antagonister |
PT2175859E (pt) | 2007-07-12 | 2012-06-06 | Chemocentryx Inc | Heteroarilpiridil- e fenil-benzenossulfonamidas condensadas como moduladores de ccr2 para o tratamento de inflamação |
EP2237798A2 (en) * | 2007-12-12 | 2010-10-13 | Imperial Innovations Limited | Methods |
HUP0800478A2 (en) | 2008-07-31 | 2010-03-01 | Sanofi Aventis | Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands |
WO2010069979A1 (en) | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
WO2010070032A1 (en) | 2008-12-19 | 2010-06-24 | Boehringer Ingelheim International Gmbh | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
MX2011010964A (es) | 2009-04-17 | 2011-11-02 | Janssen Pharmaceutica Nv | Antagonistas del receptor 2 de citocina quimioatrayente de 4- azetidinil-1-fenil-ciclohexano. |
US8471004B2 (en) | 2009-10-07 | 2013-06-25 | Hoffman-La Roche Inc. | Bicyclic compounds |
US8445674B2 (en) | 2009-10-21 | 2013-05-21 | Hoffmann-La Roche Inc | Heterocyclyl compounds |
JP5356323B2 (ja) * | 2010-07-01 | 2013-12-04 | 富士化学工業株式会社 | 新規な非晶質ボセンタン及びその製造方法 |
WO2012051090A1 (en) | 2010-10-11 | 2012-04-19 | Axikin Pharmaceuticals, Inc. | Salts of arylsulfonamide ccr3 antagonists |
MX345146B (es) | 2010-12-01 | 2017-01-17 | Janssen Pharmaceutica Nv | Ciclohexilamino-4-piperidinil-acetamida sustituida en 4 antagonista de ccr2. |
US20140005174A1 (en) | 2011-03-17 | 2014-01-02 | Anilkumar G. Nair | Indole derivatives useful as ccr2 antagonists |
WO2012138880A2 (en) | 2011-04-07 | 2012-10-11 | The Brigham And Women's Hospital, Inc. | Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2) |
KR20140022048A (ko) * | 2011-05-25 | 2014-02-21 | 인터뮨, 인크. | 선택된 환자에서의 피르페니돈 및 항-섬유성 치료제 |
EP3257519B8 (en) | 2011-06-27 | 2020-06-03 | Sorbonne Universite | Ccr2 antagonist peptides |
WO2013052844A1 (en) * | 2011-10-07 | 2013-04-11 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
WO2013057545A1 (en) * | 2011-10-18 | 2013-04-25 | Biocon Limited | Acid addition salts of bosentan |
US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
CN105377251A (zh) * | 2013-03-01 | 2016-03-02 | 马特医疗研究中心有限公司 | 动员剂及其用途 |
WO2014143807A2 (en) * | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
-
2015
- 2015-01-28 EP EP19197843.6A patent/EP3613435A1/en not_active Withdrawn
- 2015-01-28 EP EP15152886.6A patent/EP3050574B1/en active Active
- 2015-01-28 ES ES15152886T patent/ES2764840T3/es active Active
- 2015-01-28 DK DK15152886.6T patent/DK3050574T3/da active
-
2016
- 2016-01-28 WO PCT/EP2016/051771 patent/WO2016120369A1/en active Application Filing
- 2016-01-28 CN CN201680008472.9A patent/CN107405405B/zh active Active
- 2016-01-28 US US15/547,099 patent/US10813911B2/en active Active
- 2016-01-28 EA EA201791689A patent/EA201791689A1/ru unknown
- 2016-01-28 CA CA2972319A patent/CA2972319C/en active Active
- 2016-01-28 JP JP2017540788A patent/JP7127988B2/ja active Active
- 2016-01-28 BR BR112017016347-0A patent/BR112017016347A2/pt not_active Application Discontinuation
- 2016-01-28 AU AU2016212067A patent/AU2016212067B2/en active Active
-
2017
- 2017-07-27 IL IL253688A patent/IL253688B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3613435A1 (en) | 2020-02-26 |
ES2764840T3 (es) | 2020-06-04 |
CA2972319C (en) | 2023-08-01 |
AU2016212067B2 (en) | 2020-10-08 |
IL253688A (en) | 2017-09-28 |
JP7127988B2 (ja) | 2022-08-30 |
AU2016212067A1 (en) | 2017-09-14 |
EP3050574B1 (en) | 2019-10-09 |
IL253688B1 (en) | 2023-01-01 |
BR112017016347A2 (pt) | 2018-03-27 |
US20180271831A1 (en) | 2018-09-27 |
WO2016120369A1 (en) | 2016-08-04 |
JP2018505187A (ja) | 2018-02-22 |
CN107405405B (zh) | 2021-05-11 |
US10813911B2 (en) | 2020-10-27 |
IL253688B2 (en) | 2023-05-01 |
CN107405405A (zh) | 2017-11-28 |
EA201791689A1 (ru) | 2017-11-30 |
EP3050574A1 (en) | 2016-08-03 |
CA2972319A1 (en) | 2016-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3445773T3 (da) | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf | |
DK3684423T3 (da) | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf | |
DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
DK3600281T3 (da) | Kombinationsbehandling til behandling eller forebyggelse af tumorer | |
DK3285803T3 (da) | Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine | |
DK3472183T3 (da) | Variant adeno-associerede virus og fremgangsmåder til anvendelse | |
DK3227675T3 (da) | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom | |
DK3395359T3 (da) | Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose | |
DK3693158T3 (da) | Asymmetrisk forarbejdningsfremgangsmåde til krumningsreduktion i laminatstrukturer | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3203997T3 (da) | Valproinsyre til behandling eller forebyggelse af patologiske tilstande forbundet med overskydende fibrinaflejring og/eller trombedannelse | |
DK3432899T3 (da) | Anvendelse af probiotika ved behandling og/eller forebyggelse af psoriasis | |
DK3558280T3 (da) | Forebyggelse og behandling af migræne | |
DK3157531T3 (da) | Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil | |
DK3261642T3 (da) | Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner | |
DK3362449T3 (da) | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose | |
DK3217963T3 (da) | Fremgangsmåder til behandling af individer med prader-willis syndrom eller smith-magenis syndrom | |
DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
DK3532064T3 (da) | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser | |
DK3512506T3 (da) | Anvendelse af pridopidin til behandling af retts syndrom | |
DK3174559T3 (da) | Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer | |
DK3153511T3 (da) | 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme | |
DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme | |
DK3157532T3 (da) | Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet | |
DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi |